← Browse by Condition
Medical Condition

glomerulonephritis minimal lesion

Total Trials
1
Recruiting Now
1
Trial Phases
Phase 2
NCT06500702 Phase 2
Recruiting

A Study to Evaluate the Efficacy and Safety of Frexalimab, Brivekimig, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change Disease

Enrollment
84 pts
Location
United States, Argen...
Sponsor
Sanofi
View Trial →